Endurant Capital Management LP Macrogenics Inc Transaction History

Endurant Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$19.41 - $26.0 $1.89 Million - $2.53 Million	-97,374 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$24.69 - $31.6 $2.4 Million - $3.08 Million	97,374 New	97,374 $2.45 Million
Q2 2020 Aug 14, 2020	SELL	$5.2 - $29.12 $456,055 - $2.55 Million	-87,703 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$4.28 - $12.11 $150,643 - $426,235	-35,197 Reduced 28.64%	87,703 $510,000
Q4 2019 Feb 14, 2020	BUY	$7.95 - $12.27 $977,055 - $1.51 Million	122,900 New	122,900 $1.34 Million
Q4 2018 Feb 14, 2019	SELL	$11.75 - $21.42 $463,608 - $845,147	-39,456 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$19.26 - $23.46 $759,922 - $925,637	39,456 New	39,456 $846,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $195M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.